Large variety of 6 billion injections, this Guangdong pharmaceutical company has reviewed

On April 23, the NMPA official website showed that Guangdong Jincheng Jinsu Pharmaceutical's ceftazidime for injection passed the consistency evaluation. Ceftazidime for injection is the fifth batch of varieties to be collected. According to data from Minai.com, terminal ceftazidime sales in China's public medical institutions exceeded 6 billion yuan in 2019.

Ceftazidime belongs to the third-generation semi-synthetic cephalosporins. It has the characteristics of a broad antibacterial spectrum and enzyme resistance. It is suitable for the treatment of single or multiple infections caused by sensitive microorganisms, such as systemic severe infections, lower respiratory tract infections, ear, nose, and throat infections, and urine. Road infection and so on. Ceftazidime is in the 2018 National Essential Drug List and the 2020 National Essential Medical Insurance List, and the original manufacturer is GlaxoSmithKline.

According to data from Meinenet, in 2019, the sales of ceftazidime for terminal injection in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 6 billion yuan, and its sales in 2020H1 were close to 2.5 billion yuan. , Hainan Hailing Chemical Pharmaceutical occupies more than 50% of the market share.

Sales of terminal ceftazidime in public medical institutions in China

Source: Mi Nei.com, China's public medical institutions terminal competition pattern

Ceftazidime for injection is the fifth batch of varieties to be collected. According to the consistency evaluation database of Meinenet, there are currently 7 companies that have over-rated ceftazidime for injection, including Qilu Pharmaceutical, Better Pharmaceutical, Yangtze River Pharmaceutical, Hanmi Pharmaceutical, Hailing Pharmaceutical, Jincheng Jinsu, and Hainan Herui Pharmaceutical.

Up to now, Jincheng Jinsu has passed the consistency evaluation of 3 injections, including Cefazolin Sodium for Injection, Ceftriaxone Sodium for Injection, and Ceftazidime for Injection, all of which are the fifth batch of varieties to be collected.

Source: Mi Neiwang database, NMPA